Publications and Presentations
Manufacture Of AVB-406, A BBB-Crossing AAV Vector For MAPT Knockdown In Alzheimer’s Disease
Date: Nov 12, 2026
Conference / Journal: Cell 2026
Author(s): Michael MacDonald, DPhil
vMiX: A Modular AAV-Delivered miRNA Platform For Precise, Durable Gene Silencing Across Indications
Date: Nov 12, 2026
Conference / Journal: Cell 2026
Author(s): Romain Joubert, PhD
Preclinical development of AVB-406: An intravenous AAV-miRNA achieving sustained MAPT knockdown for the treatment of Alzheimer’s disease and other tauopathies
Date: Oct 29, 2026
Conference / Journal: ESGCT 2026
Author(s): Deirdre O'Connor
Silencing of MAPT via AVB-406 in human iPSC-derived neurons: A translational framework for neurodegenerative diseases
Date: Oct 29, 2026
Conference / Journal: ESGCT 2026
Presenter: Martina Esposito Soccoio
Author(s): M. Esposito Soccoio, R. Elsayed, M.L. Reilly, L.S. Brebner, A. Abhilash, D. Cox, M. Donnelly, M. MacDonald, M. Sztyler, J. Kenth-Shah, G. Kooner, A. Martorana, P. Boyce, C. Andreassi, A. Bloom, R. Joubert
Evaluation of rationally designed synthetic promoters for expression in neurons and glial cells
Date: Oct 29, 2026
Conference / Journal: ESGCT 2026
Presenter: Daniel Cox
Author(s): D. Cox, T. Waibel, K. Baker, R. Palacios, A. Evripioti, M. Esposito Soccoio, M.L. Reilly, L.S. Brebner, A. Abhilash, A. Bloom, R. Joubert, M. Roberts, G. Kooner
Leveraging the vMiX™ platform to target alpha-synuclein for the treatment of Parkinson’s disease and other synucleinopathies
Date: Oct 28, 2026
Conference / Journal: ESGCT 2026
Presenter: Guillaume Lo
Author(s): G. Lo, D. Dey, L.S. Brebner, R. Elsayed, M. Donnelly, M. MacDonald, A. Martorana, L. Reilly, E. Dellow, D. Ojutalayo, M. Esposito Soccoio, C. Andreassi, Z. Walker, C.E. Shaw, B. Mota, N.A.M. Nafchi, D. O’Connor, C.J. Miranda, A. Bloom, R. Joubert
ASPIRE-FTD in FTD with GRN Mutations Study Update: A Phase 1/2 Study to Evaluate AVB-101
Date: Oct 19, 2026
Conference / Journal: ISFTD 2026
Presenter: Prof. Rik Vandenberghe, KU Leuven
Author(s): G. Di Fede, G. Klodowska, J.C. Masdeu, B. Pascual, M. Ratajczak, J.D. Rohrer, M. Czarnecki, R.R. Darby, A.G. Murley, J.B. Rowe, R. Vandenberghe, M. Zabek, J.B. Elder, W. Gray, V. Levi, H. Bjartmarz, J.Y.C. Chan, Y.-G. Huang, C.M. Powell, D.L. Cooper
Development of a Translational Assay for Identification and Quantitation of Orthologous Proteins to Aid Drug Development in Preclinical Models
Date: Sep 17, 2026
Conference / Journal: Journal of Proteome Research
Author(s): Blandine Rougemont, Julie Borgel, Zoe Walker, Irene Zubiri, Ronan O’Cualain, Neda Ali Mohammadi Nafchi, Christopher E. Shaw, Ernestas Sirka, John Isaac, Carlos J. Miranda, and Anna Ettorre
ASPIRE-FTD Study Update: A Phase 1/2 Clinical Study to Evaluate AVB-101 in FTD with GRN Mutations
Date: Jul 14, 2026
Conference / Journal: AAIC 2026
Author(s): G. Klodowska, J.C. Masdeu, B. Pascual, M. Ratajczak, M. Czarnecki, R.R. Darby, A.G. Murley, J.D. Rohrer, J.B. Rowe, M. Zabek, J.B. Elder, W. Gray, C.M. Powell, J.Y.C. Chan, Y.-G. Huang, D.L. Cooper
Development and translational validation of AVB-406: an intravenous AAV-miRNA targeting MAPT for the treatment of Alzheimer’s disease
Date: Jul 14, 2026
Conference / Journal: AAIC 2026
Author(s): Romain Joubert, Madeline Louise Reilly, Deirdre O’Connor, Gurdeep Kooner, Leonie Sophie Brebner, Deborah Ojutalayo, Martina Esposito Soccoio, Randa Elsayed, Catia Andreassi, Emily Dellow, Bibiana C Mota, Neda Ali Mohammadi, Andrea Martorana, Michael MacDonald, Peter Boyce, Agnieszka M Ule, Carlos J Miranda, Christopher E Shaw, John Isaac, Alex Bloom
Preclinical Development Of AVB-406: An Intravenous AAV-miRNA Achieving Sustained MAPT Knockdown To Treat Alzheimer’s Disease
Date: Jul 13, 2026
Conference / Journal: AAIC 2026
Author(s): Deirdre M. O’Connor, Emily Dellow, Bibiana C. Mota, Neda A. Mohammadi, Anna Ettorre, Zoe Walker, Amrita Abhilash, Gurdeep Kooner, Megan Donnelly, Andrea Martorana, Magda Sztyler, Jaya Kenth-Shah, Josh H. Yeung, Quwam Akinlawon, Guillaume Lo, Douglass Dey, Daniel Cox, Peter Boyce, Romain Joubert, Chris E. Shaw, Alex Bloom, John Isaac, Carlos J. Miranda
Development and translational validation of AVB-406: An intravenous AAV-delivered miRNA targeting MAPT for the treatment of Alzheimer’s disease
Date: May 14, 2026
Conference / Journal: ASGCT 2026
Author(s): Romain Joubert
AviadoBio is relentlessly chasing cures by developing and translating groundbreaking science and precision delivery into life-changing medicines across neurodegenerative diseases.
© AviadoBio Ltd, 2026. All rights reserved.
